Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Jul 04 2023

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 2 pages · English

Summary by 6ix AI

Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Oxcarbazepine Tablets in various strengths. The tablets are used to treat seizure disorders and will be manufactured in Baddi, Himachal Pradesh.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange regarding a press release dated July 04, 2023, titled "Zydus receives final approval from the USFDA for Oxcarbazepine Tablets USP, 150 mg, 300 mg and 600 mg".

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases